Project Grant RF1AG088226
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$2.5M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Orangeburg, NY 10962, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $341,000 in funding to The Roskamp Institute, Inc. in Sarasota, FL to conduct research aimed at understanding and correcting brain bioenergetics defects associated with the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research will examine the influence of different APOE genotypes on the GLP-1R-AMPK-ACC pathway in cerebrovascular cells and astrocytes, and evaluate...
This $1,559,999 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a comprehensive study to elucidate the regulation of the APOE gene and the role of the AANCR noncoding RNA in Alzheimer's disease. The research aims to gain a deeper understanding of how APOE expression and genotypes, particularly the risk-associated APOE4 allele, affect cellular function in stress-activated astrocytes and microglia, and the subsequent impact on neuronal health....
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $3,477,475 to the Icahn School of Medicine at Mount Sinai to investigate the combined role of the APOE4 gene variant and ketogenic diets in the development of Alzheimer's disease (AD). The award will fund a 5-year research study aimed at elucidating the molecular mechanisms by which APOE4 interacts with high-fat/ketogenic diets to exacerbate AD pathogenesis. The research will employ in vitro...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $4,694,672 to North Dakota State University from May 15, 2021 through April 30, 2024. The funding supports research to design a non-viral gene delivery system for delivering an APOE2 plasmid to the brain. Specifically, the university will synthesize and characterize liposomal nanoparticles loaded with chitosan-APOE2 polyplexes and modified with transferrin and cell-penetrating peptides...
The National Institute on Aging (NIA) awarded a $1,649,586 Project Grant under the Aging Research (CFDA 93.866) federal grant program to the Sanford Burnham Prebys Medical Discovery Institute. The award will fund a 5-year project to discover and optimize small molecule "correctors" that can restore the thermal stability of the Alzheimer's disease risk factor protein APOE4 to be functionally similar to the protective APOE3 variant. The project aims to develop a high-throughput...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $804,450.00 to the J. David Gladstone Institutes in San Francisco, CA to investigate the mechanisms by which the Alzheimer's disease risk factor APOE4 and sex differences contribute to network hyperactivity and selective neuronal dysfunction in Alzheimer's disease. The research aims to validate the protective effects of the NELL2 protein in hippocampal excitatory neurons and examine...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $682,000 to The Roskamp Institute, Inc. to investigate the influence of microglial cell depletion and repopulation on amyloid-related imaging abnormalities (ARIA) and vascular lesions in individuals with Alzheimer's disease who carry the APOE4 genotype. The study aims to characterize the impact of microglial activation on cerebrovascular integrity and function following treatment with the...